Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.51 |
| ▸ | KDR | P35968 | 13/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128295 | 0.84 | CYP3A4 (0.69) | BRAFKDRCYP3A4RAF1FLT3 | |
| SCHEMBL4358365 | 0.82 | ABL1 (0.57) | BRAFKDRCYP3A4FLT3ABL1 | |
| SCHEMBL4363438 | 0.81 | CYP3A4 (0.49) | BRAFKDRCYP3A4FLT3ABL1 | |
| SCHEMBL4354281 | 0.79 | CYP3A4 (0.47) | BRAFKDRCYP3A4FLT3ABL1 | |
| SCHEMBL4357191 | 0.79 | PDE9A (0.44) | KDRCYP3A4FLT3ABL1EGFR | |
| SCHEMBL1128845 | 0.76 | CYP3A4 (0.55) | BRAFKDRCYP3A4FLT3ABL1 | |
| SCHEMBL1128588 | 0.75 | CYP3A4 (0.70) | CYP3A4FLT3 | |
| Trifluoroacetic Acid SCHEMBL1128524 | 0.74 | CYP3A4 (0.68) | BRAFCYP3A4FLT3ABL1BCR | |
| SCHEMBL4358055 | 0.74 | CYP3A4 (0.48) | CYP3A4FLT3ABL1BCR | |
| SCHEMBL4357333 | 0.74 | CYP3A4 (0.42) | KDRCYP3A4PDGFRBPDGFRAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | BRAF 4580/4885KDR 561/4885CYP3A4 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.